Alan A. Melcher

This study identifies functionally heterogeneous cancer-associated fibroblasts in muscle-invasive bladder cancer linked to poor radiotherapy outcomes.

This paper shows that intratumoural oncolytic HSV-1 reprograms systemic immunity by inducing specific CD8 T cell populations that correlate with clinical response to immunotherapy.

This study evaluates a second-generation STING agonist, BI-1703880, showing that combining it with radiotherapy enhances antitumour immunity and immune memory.

This study shows that chemoradiotherapy (CRT) in head and neck cancer promotes clonal dominance of progenitor-exhausted CD8+ T-cells compared to radiotherapy alone.

This paper introduces CanonicalTockySeq to analyze T-cell fate decisions over time in immunotherapy, showing that effective treatment correlates with reduced antigen engagement and exhaustion signaling.

This study shows that radiation-induced podoplanin-positive fibroblasts limit CD8+ T-cell access to tumour cells, reducing radiotherapy effectiveness, and that disrupting PDPN signaling enhances tumour control.

This paper identifies PARP inhibitors as sensitizers for oncolytic reovirus by enhancing DISC-mediated apoptosis and NF-kappa B-driven immune responses.

This study identifies PBAF as a protector of centromere and pericentromere structure, showing that PBRM1 loss leads to centromere fragility and therapeutic vulnerability.

This study uses oncolytic viruses to deliver miRNA to TAMs, reversing their immunosuppressive activity and improving ovarian cancer immunotherapy efficacy.

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

This study shows that combining oncolytic Maraba virus with PD-1 blockade overcomes resistance in advanced melanoma with a cold tumor microenvironment.

This paper shows that uv-inactivated reovirus combined with sorafenib improves survival in HCC by promoting IFNβ-induced cytotoxic CD4+ T-cell responses that are MHCII-independent.

This study identifies resistance mutations in cancer that may have immunogenic potential, with some validated to elicit T-cell responses.